Compare NEXT & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEXT | IOVA |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2014 | 2008 |
| Metric | NEXT | IOVA |
|---|---|---|
| Price | $7.65 | $4.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $8.00 | ★ $9.00 |
| AVG Volume (30 Days) | 3.0M | ★ 13.4M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $47.74 |
| Revenue Next Year | N/A | $40.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.75 | $1.70 |
| 52 Week High | $12.12 | $5.63 |
| Indicator | NEXT | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 48.16 | 57.19 |
| Support Level | $6.81 | $2.07 |
| Resistance Level | $8.93 | $4.35 |
| Average True Range (ATR) | 0.43 | 0.33 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 66.67 | 56.85 |
NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas, the sale of LNG, and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions, advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.